Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study
Aline Tanguy-Schmidt, Philippe Rousselot, Yves Chalandon, Jean-Michel Cayuela, Sandrine Hayette, Marie-Christiane Vekemans, Martine Escoffre, Françoise Huguet, Delphine Réa, André Delannoy, Jean-Yves Cahn, Jean-Paul Vernant, Norbert Ifrah, Hervé Dombret, Xavier Thomas, Aline Tanguy-Schmidt, Philippe Rousselot, Yves Chalandon, Jean-Michel Cayuela, Sandrine Hayette, Marie-Christiane Vekemans, Martine Escoffre, Françoise Huguet, Delphine Réa, André Delannoy, Jean-Yves Cahn, Jean-Paul Vernant, Norbert Ifrah, Hervé Dombret, Xavier Thomas
Abstract
We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Imatinib-based strategy improved the 4-year overall survival (OS) up to 52% versus 20% in the pre-imatinib LALA-94 trial (P = .0001). Despite the selection in patients who actually underwent transplantation, these results suggest that allogeneic or autologous stem cell transplants (SCTs) still have a place in overcoming the poor prognosis of Ph+ ALL in the era of imatinib therapy. OS was 50% after allogeneic SCT (24 patients), 33% in patients without a transplantation (9 patients), and 80% after autologous SCT (10 patients without allogeneic donor or >55 years, including 7 patients in complete molecular response).
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Source: PubMed